New combo therapy aims to shrink throat tumors before standard treatment
NCT ID NCT07428148
First seen Feb 28, 2026 · Last updated May 01, 2026 · Updated 14 times
Summary
This study tests a new approach for people with a type of throat cancer (oropharyngeal squamous cell carcinoma) that is not low-risk. About 60 participants will receive a combination of immunotherapy, chemotherapy, and a special type of radiation called lattice radiotherapy before standard chemoradiation. The goal is to shrink the tumor by at least half and then tailor the final radiation dose based on how well the tumor responded.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
New York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.